CV Safety Study of Cancer Therapy Attracts Attention

Although the first global trial to compare the cardiovascular (CV) safety of two therapies for prostate cancer proved inconclusive, it was “a model for interdisciplinary collaboration” says investigator.
Medscape Medical News